Core Viewpoint - The announcement from Keda Xunfei (002230) regarding its 2025 annual performance forecast indicates a projected net profit growth of 40% to 70% year-on-year, highlighting the resilience of its core business and signaling that AI-driven vertical scene commercialization has entered a harvest phase [1] Group 1: Company Performance - Keda Xunfei's growth is attributed to its "platform + scene" strategy, with the medical sector being a significant contributor to this growth [1] - The medical segment has achieved substantial market penetration, with core product "Smart Medical Assistant" deployed in over 77,000 grassroots medical institutions nationwide [2] - The company reported that its medical AI projects won contracts worth 2.316 billion yuan in 2025, surpassing the combined total of the second to sixth competitors in the industry [3] Group 2: Technological Advancements - The "Xunfei Spark" large model is the only mainstream model in China trained on domestically produced computing power, maintaining competitive technical indicators globally [3] - The medical deep reasoning model, based on the Spark model, has outperformed competitors like GPT-5 and DeepSeek V3.2-Exp in various medical applications [3] - The company has established a complete ecosystem combining large models, data, and application scenarios, creating a competitive advantage that is difficult for peers to replicate [7] Group 3: Market Trends - The global AI medical market is projected to exceed $100 billion by 2025, with a compound annual growth rate of over 25%, particularly in grassroots medical AI applications [5] - Keda Xunfei is positioned to provide replicable solutions for global healthcare challenges, leveraging its experience in the Chinese market [6] - The company is seen as a leader in the AI medical sector, with its valuation expected to rise as it continues to optimize its business model and maintain its technological barriers [7] Group 4: Future Outlook - The performance forecast serves as a confidence vote for the commercialization of AI, indicating that Keda Xunfei's medical technology is not only a spillover effect from its parent company but also a signal of its independent commercial value [8] - The company is on a unique path of AI medical commercialization, deeply embedded in the transformation of the Chinese healthcare system [8]